Vlastníctvo manažmentu spoločnosti Amgen

Aká je hodnota metriky Vlastníctvo manažmentu spoločnosti Amgen?

Hodnota metriky Vlastníctvo manažmentu spoločnosti Amgen, Inc. je 0.22%

Aká je definícia metriky Vlastníctvo manažmentu?



Vlastníctvo manažmentu (Insider Ownership) je pomer akcií vlastnených akcionármi v rámci firmy (vlastniaci viac než 5% spoločnosti alebo s titulom riaditeľa či vedúceho oddelenia) a všetkých vydaných akcií.

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

Vlastníctvo manažmentu spoločností v sektore Health Care sektor na XETRA v porovnaní so spoločnosťou Amgen

Čomu sa venuje spoločnosť Amgen?

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Firmy s metrikou vlastníctvo manažmentu podobnou spoločnosti Amgen



  • Hodnota metriky Vlastníctvo manažmentu spoločnosti The Travelers Companies je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti NB Private Equity Partners je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti Weyerhaeuser Co je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti NB Private Equity Partners je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti CTI BioPharma Corp je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti Signify N.V je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti Amgen je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti Xilinx je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti Xilinx je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti Xilinx je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti Northrop Grumman je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti Fox Factory Corp je 0.22%
  • Hodnota metriky Vlastníctvo manažmentu spoločnosti CSX je 0.22%